Skip to main content
Erschienen in: Endocrine 3/2024

22.09.2023 | Original Article

The impact of microscopic extrathyroidal extension on the clinical outcome of classic subtype papillary thyroid microcarcinoma: a multicenter study

verfasst von: Sayid Shafi Zuhur, Hunkar Aggul, Ugur Avci, Selvinaz Erol, Mazhar Muslum Tuna, Serhat Uysal, Gulhan Akbaba, Faruk Kilinc, Merve Catak, Sakin Tekin, Beyza Olcay Ozturk, Halise Cinar Yavuz, Pinar Kadioglu, Nese Cinar, Taner Bayraktaroglu, Birol Topcu, Yuksel Altuntas, Gulsah Elbuken

Erschienen in: Endocrine | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Despite the presumed overdiagnosis of papillary thyroid microcarcinoma (PTMC) which has resulted in a new trend toward less-extensive surgery and a preference for active surveillance, the impact of microscopic extrathyroidal extension (mETE) on the clinical outcomes of PTMC is still controversial. This study assessed the impact of mETE on the clinical outcomes of patients with classic subtype PTMC.

Methods

The data of consecutive patients who underwent thyroidectomy and were histopathologically diagnosed as classic subtype PTMC were analyzed. Cox’s proportional hazards model was used to assess the impact of contributing variables on persistent/recurrent disease. Disease-free survival was estimated using the Kaplan-Meier method.

Results

This study included 1013 patients (84% females), with a mean follow-up period of 62.5 ± 35.3 months. Patients with mETE had a significantly higher rate of locoregional persistent/recurrent disease than patients without mETE (9.8% vs 2.1%, p < 0.001). The disease-free survival rate was significantly lower in patients with mETE than in those without (90.2% vs 97%, Log-Rank p < 0.001). Furthermore, mETE and neck lymph node involvement were independent predictors of persistent/recurrent disease in multivariate analysis (HR: 2.43, 95% CI:1.02–5.81, p = 0.043; HR: 4.38, 95% CI: 1.7–11.2, p = 0.002, respectively).

Conclusions

In patients with the classic subtype of PTMC, mETE is an independent predictor of persistent/recurrent disease and is associated with a lower DFS rate. However, neck lymph node involvement is the strongest predictor of persistent/recurrent disease. Therefore, PTMCs with mETE and neck lymph node involvement are at a higher risk of persistent/recurrent disease than individuals lacking both characteristics.
Literatur
1.
Zurück zum Zitat M. Pereira, V.L. Williams, J. Hallanger Johnson, P. Valderrabano, Thyroid cancer incidence trends in the United States: Association with changes in professional guideline recommendations. Thyroid 30, 1132–1140 (2020)CrossRefPubMed M. Pereira, V.L. Williams, J. Hallanger Johnson, P. Valderrabano, Thyroid cancer incidence trends in the United States: Association with changes in professional guideline recommendations. Thyroid 30, 1132–1140 (2020)CrossRefPubMed
3.
Zurück zum Zitat D.T. Hughes, M.R. Haymart, B.S. Miller, P.G. Gauger, G.M. Doherty, The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid 21, 231–236 (2011)CrossRefPubMed D.T. Hughes, M.R. Haymart, B.S. Miller, P.G. Gauger, G.M. Doherty, The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid 21, 231–236 (2011)CrossRefPubMed
5.
Zurück zum Zitat M. Van Gerwen, N. Alpert, C. Sinclair, M. Kale, E. Genden, E. Taioli, Assessing non-aggressiveness of untreated, local and regional, papillary thyroid cancer. Oral. Oncol. 105, 104674 (2020)CrossRefPubMed M. Van Gerwen, N. Alpert, C. Sinclair, M. Kale, E. Genden, E. Taioli, Assessing non-aggressiveness of untreated, local and regional, papillary thyroid cancer. Oral. Oncol. 105, 104674 (2020)CrossRefPubMed
6.
Zurück zum Zitat S.S. Zuhur, H. Aggul, U. Avci et al. Do histologically aggressive subtypes of papillary thyroid microcarcinoma have worse clinical outcome than non-aggressive papillary thyroid microcarcinoma subtypes? A multicenter cohort study. Horm. Metab. Res 10, 2032–5810 (2023) S.S. Zuhur, H. Aggul, U. Avci et al. Do histologically aggressive subtypes of papillary thyroid microcarcinoma have worse clinical outcome than non-aggressive papillary thyroid microcarcinoma subtypes? A multicenter cohort study. Horm. Metab. Res 10, 2032–5810 (2023)
7.
Zurück zum Zitat S. Leboulleux, R.M. Tuttle, F. Pacini, M. Schlumberger, Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol. 4, 933–942 (2016)CrossRefPubMed S. Leboulleux, R.M. Tuttle, F. Pacini, M. Schlumberger, Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol. 4, 933–942 (2016)CrossRefPubMed
8.
Zurück zum Zitat H.J. Moon, E.K. Kim, W.Y. Chung, J.H. Yoon, J.Y. Kwak, Minimal extrathyroidal extension in patients with papillary thyroid microcarcinoma: is it a real prognostic factor? Ann. Surg. Oncol. 18, 1916–1923 (2011)CrossRefPubMed H.J. Moon, E.K. Kim, W.Y. Chung, J.H. Yoon, J.Y. Kwak, Minimal extrathyroidal extension in patients with papillary thyroid microcarcinoma: is it a real prognostic factor? Ann. Surg. Oncol. 18, 1916–1923 (2011)CrossRefPubMed
9.
Zurück zum Zitat N. Chéreau, C. Buffet, C. Trésallet et al. Does extracapsular extension impact the prognosis of papillary thyroid microcarcinoma? Ann. Surg. Oncol. 21, 1659–1664 (2014)CrossRefPubMed N. Chéreau, C. Buffet, C. Trésallet et al. Does extracapsular extension impact the prognosis of papillary thyroid microcarcinoma? Ann. Surg. Oncol. 21, 1659–1664 (2014)CrossRefPubMed
10.
Zurück zum Zitat C. Buffet, J.L. Golmard, C. Hoang et al. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. Eur. J. Endocrinol. 167, 267–275 (2012)CrossRefPubMed C. Buffet, J.L. Golmard, C. Hoang et al. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. Eur. J. Endocrinol. 167, 267–275 (2012)CrossRefPubMed
11.
Zurück zum Zitat R.Y. Song, H.S. Kim, K.H. Kang, Minimal extrathyroidal extension is associated with lymph node metastasis in single papillary thyroid microcarcinoma: a retrospective analysis of 814 patients. World J. Surg. Oncol. 20, 170 (2022)CrossRefPubMedPubMedCentral R.Y. Song, H.S. Kim, K.H. Kang, Minimal extrathyroidal extension is associated with lymph node metastasis in single papillary thyroid microcarcinoma: a retrospective analysis of 814 patients. World J. Surg. Oncol. 20, 170 (2022)CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat F. Pacini, M. Schlumberger, H. Dralle et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787–803 (2006)CrossRefPubMed F. Pacini, M. Schlumberger, H. Dralle et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787–803 (2006)CrossRefPubMed
13.
Zurück zum Zitat M.B. Amin, S. Edge, F. Greene, et al. AJCC Cancer Staging Manual. 8th ed. Springer 881–889 (2017). M.B. Amin, S. Edge, F. Greene, et al. AJCC Cancer Staging Manual. 8th ed. Springer 881–889 (2017).
14.
Zurück zum Zitat D.S. Cooper, G.M. Doherty et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167e1214 (2009)CrossRef D.S. Cooper, G.M. Doherty et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167e1214 (2009)CrossRef
15.
Zurück zum Zitat B.R. Haugen, E.K. Alexander, K.C. Bible et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)CrossRefPubMedPubMedCentral B.R. Haugen, E.K. Alexander, K.C. Bible et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat S.S. Zuhur, H. Aggul, M. Çelik et al. Can age at diagnosis and sex improve the performance of the american thyroid association risk stratification system for prediction of structural persistent and recurrent disease in patients with differentiated thyroid carcinoma? a multicenter study. Endocr. Pr. 28, 30–35 (2022)CrossRef S.S. Zuhur, H. Aggul, M. Çelik et al. Can age at diagnosis and sex improve the performance of the american thyroid association risk stratification system for prediction of structural persistent and recurrent disease in patients with differentiated thyroid carcinoma? a multicenter study. Endocr. Pr. 28, 30–35 (2022)CrossRef
17.
Zurück zum Zitat D.P. Momesso, R.M. Tuttle, Update on differentiated thyroid cancer staging. Endocrinol. Metab. Clin. North Am. 43, 401–421 (2014)CrossRefPubMed D.P. Momesso, R.M. Tuttle, Update on differentiated thyroid cancer staging. Endocrinol. Metab. Clin. North Am. 43, 401–421 (2014)CrossRefPubMed
18.
Zurück zum Zitat A. Jang, M. Jin, C.A. Kim et al. Serum thyroglobulin testing after thyroid lobectomy in patients with 1-4 cm papillary thyroid carcinoma. Endocrine 81, 290–297 (2023)CrossRefPubMed A. Jang, M. Jin, C.A. Kim et al. Serum thyroglobulin testing after thyroid lobectomy in patients with 1-4 cm papillary thyroid carcinoma. Endocrine 81, 290–297 (2023)CrossRefPubMed
19.
Zurück zum Zitat H. Mehanna, T. Al-Maqbili, B. Carter et al. Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up. J. Clin. Endocrinol. Metab. 99, 2834–2843 (2014)CrossRefPubMed H. Mehanna, T. Al-Maqbili, B. Carter et al. Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up. J. Clin. Endocrinol. Metab. 99, 2834–2843 (2014)CrossRefPubMed
20.
Zurück zum Zitat Y. Ito, C. Tomoda, T. Uruno et al. Minimal extrathyroid extension does not affect the relapse-free survival of patients with papillary thyroid carcinoma measuring 4 cm or less over the age of 45 years. Surg. Today 36, 12–18 (2006)CrossRefPubMed Y. Ito, C. Tomoda, T. Uruno et al. Minimal extrathyroid extension does not affect the relapse-free survival of patients with papillary thyroid carcinoma measuring 4 cm or less over the age of 45 years. Surg. Today 36, 12–18 (2006)CrossRefPubMed
21.
Zurück zum Zitat I.D. Hay, T.R. Johnson, G.B. Thompson, T.J. Sebo, M.S. Reinalda, Minimal extrathyroid extension in papillary thyroid carcinoma does not result in increased rates of either cause-specific mortality or postoperative tumor recurrence. Surgery 159, 11–19 (2016)CrossRefPubMed I.D. Hay, T.R. Johnson, G.B. Thompson, T.J. Sebo, M.S. Reinalda, Minimal extrathyroid extension in papillary thyroid carcinoma does not result in increased rates of either cause-specific mortality or postoperative tumor recurrence. Surgery 159, 11–19 (2016)CrossRefPubMed
22.
Zurück zum Zitat Y. Ito, C. Tomoda, T. Uruno et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J. Surg. 30, 780–786 (2006)CrossRefPubMed Y. Ito, C. Tomoda, T. Uruno et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J. Surg. 30, 780–786 (2006)CrossRefPubMed
23.
Zurück zum Zitat Z. Al-Qurayshi, N. Nilubol, R.P. Tufano, E. Kandil, Wolf in sheep’s clothing: Papillary thyroid microcarcinoma in the US. J. Am. Coll. Surg. 230, 484–491 (2020)CrossRefPubMedPubMedCentral Z. Al-Qurayshi, N. Nilubol, R.P. Tufano, E. Kandil, Wolf in sheep’s clothing: Papillary thyroid microcarcinoma in the US. J. Am. Coll. Surg. 230, 484–491 (2020)CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat T. Diker-Cohen, D. Hirsch, I. Shimon et al. Impact of minimal extra-thyroid extension in differentiated thyroid cancer: Systematic review and meta-. J. Clin. Endocrinol. Metab. 103, 2100–2106 (2018)CrossRef T. Diker-Cohen, D. Hirsch, I. Shimon et al. Impact of minimal extra-thyroid extension in differentiated thyroid cancer: Systematic review and meta-. J. Clin. Endocrinol. Metab. 103, 2100–2106 (2018)CrossRef
25.
Zurück zum Zitat R. Seifert, M.A. Schäfers, B. Heitplatz, L. Kerschke, B. Riemann, B. Noto, Minimal extrathyroid extension in papillary micro carcinoma of the thyroid is an independent risk factor for relapse through lymph node and distant metastases. J. Nucl. Med. 62, 1702–1709 (2021)CrossRefPubMedPubMedCentral R. Seifert, M.A. Schäfers, B. Heitplatz, L. Kerschke, B. Riemann, B. Noto, Minimal extrathyroid extension in papillary micro carcinoma of the thyroid is an independent risk factor for relapse through lymph node and distant metastases. J. Nucl. Med. 62, 1702–1709 (2021)CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Z.W. Baloch, S.L. Asa, J.A. Barletta et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr. Pathol. 33, 27–63 (2022)CrossRefPubMed Z.W. Baloch, S.L. Asa, J.A. Barletta et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr. Pathol. 33, 27–63 (2022)CrossRefPubMed
27.
Zurück zum Zitat J.S. Park, J.W. Chang, L. Liu, S.N. Jung, B.S. Koo, Clinical implications of microscopic extrathyroidal extension in patients with papillary thyroid carcinoma. Oral. Oncol. 72, 183–187 (2017)CrossRefPubMed J.S. Park, J.W. Chang, L. Liu, S.N. Jung, B.S. Koo, Clinical implications of microscopic extrathyroidal extension in patients with papillary thyroid carcinoma. Oral. Oncol. 72, 183–187 (2017)CrossRefPubMed
28.
Zurück zum Zitat R.M. Tuttle, B. Haugen, N.D. Perrier, Updated american joint committee on cancer/ tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth ed.): what changed and why? Thyroid 27, 751–756 (2017)CrossRefPubMedPubMedCentral R.M. Tuttle, B. Haugen, N.D. Perrier, Updated american joint committee on cancer/ tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth ed.): what changed and why? Thyroid 27, 751–756 (2017)CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat X.M. Yu, Y. Wan, R.S. Sippel, H. Chen, Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann. Surg. 254, 653–660 (2011)CrossRefPubMed X.M. Yu, Y. Wan, R.S. Sippel, H. Chen, Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann. Surg. 254, 653–660 (2011)CrossRefPubMed
30.
Zurück zum Zitat K.W. Schmid, S. Synoracki, H. Dralle et al. Proposal for an extended pTNM classification of thyroid carcinoma. Pathologe 40(Suppl 1), 18–24 (2019)CrossRefPubMed K.W. Schmid, S. Synoracki, H. Dralle et al. Proposal for an extended pTNM classification of thyroid carcinoma. Pathologe 40(Suppl 1), 18–24 (2019)CrossRefPubMed
31.
Zurück zum Zitat M.B. Amin, F.L. Greene, S.B. Edge et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J. Clin. 67, 93–99 (2017)CrossRefPubMed M.B. Amin, F.L. Greene, S.B. Edge et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J. Clin. 67, 93–99 (2017)CrossRefPubMed
32.
Zurück zum Zitat R. Forleo, G. Grani, M. Alfò et al. (2021). Minimal extrathyroidal extension in predicting 1-year outcomes: A longitudinal multicenter study of low-to-intermediate-risk papillary thyroid carcinoma (ITCO#4). Thyroid 31(12), 1814–1821 (2021)CrossRefPubMed R. Forleo, G. Grani, M. Alfò et al. (2021). Minimal extrathyroidal extension in predicting 1-year outcomes: A longitudinal multicenter study of low-to-intermediate-risk papillary thyroid carcinoma (ITCO#4). Thyroid 31(12), 1814–1821 (2021)CrossRefPubMed
33.
Zurück zum Zitat J. Lee, J.H. Park, C.R. Lee, W.Y. Chung, C.S. Park, Long-term outcomes of total thyroidectomy versus thyroid lobectomy for papillary thyroid microcarcinoma: comparative analysis after propensity score matching. Thyroid 23, 1408–1415 (2013)CrossRefPubMed J. Lee, J.H. Park, C.R. Lee, W.Y. Chung, C.S. Park, Long-term outcomes of total thyroidectomy versus thyroid lobectomy for papillary thyroid microcarcinoma: comparative analysis after propensity score matching. Thyroid 23, 1408–1415 (2013)CrossRefPubMed
34.
Zurück zum Zitat S. Leboulleux, C. Bournaud, C.N. Chougnet et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N. Engl. J. Med 386(10), 923–932 (2022)CrossRefPubMed S. Leboulleux, C. Bournaud, C.N. Chougnet et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N. Engl. J. Med 386(10), 923–932 (2022)CrossRefPubMed
35.
Zurück zum Zitat F. Pacini, D. Fuhrer, R. Elisei et al. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur. Thyroid J. 11(1), e210046 (2022)CrossRefPubMed F. Pacini, D. Fuhrer, R. Elisei et al. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur. Thyroid J. 11(1), e210046 (2022)CrossRefPubMed
37.
Zurück zum Zitat J. Pachucki, L.A. Burmeister, Evaluation and treatment of persistent thyroglobulinemia in patients with well-differentiated thyroid cancer. Eur. J. Endocrinol. 137, 254e26 (1997) J. Pachucki, L.A. Burmeister, Evaluation and treatment of persistent thyroglobulinemia in patients with well-differentiated thyroid cancer. Eur. J. Endocrinol. 137, 254e26 (1997)
38.
Zurück zum Zitat M.F. Bates, M.R. Lamas, R.W. Randle et al. Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease? Surgery 163, 118–123 (2018)CrossRefPubMed M.F. Bates, M.R. Lamas, R.W. Randle et al. Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease? Surgery 163, 118–123 (2018)CrossRefPubMed
39.
Zurück zum Zitat G. Sapuppo, M. Tavarelli, A. Belfiore, R. Vigneri, G. Pellegriti, Time to separate persistent from recurrent differentiated thyroid cancer: Different conditions with different outcomes. J. Clin. Endocrinol. Metab. 104, 258–265 (2019)CrossRefPubMed G. Sapuppo, M. Tavarelli, A. Belfiore, R. Vigneri, G. Pellegriti, Time to separate persistent from recurrent differentiated thyroid cancer: Different conditions with different outcomes. J. Clin. Endocrinol. Metab. 104, 258–265 (2019)CrossRefPubMed
Metadaten
Titel
The impact of microscopic extrathyroidal extension on the clinical outcome of classic subtype papillary thyroid microcarcinoma: a multicenter study
verfasst von
Sayid Shafi Zuhur
Hunkar Aggul
Ugur Avci
Selvinaz Erol
Mazhar Muslum Tuna
Serhat Uysal
Gulhan Akbaba
Faruk Kilinc
Merve Catak
Sakin Tekin
Beyza Olcay Ozturk
Halise Cinar Yavuz
Pinar Kadioglu
Nese Cinar
Taner Bayraktaroglu
Birol Topcu
Yuksel Altuntas
Gulsah Elbuken
Publikationsdatum
22.09.2023
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03533-1

Weitere Artikel der Ausgabe 3/2024

Endocrine 3/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.